Cancer Gene Therapy Market Report 2026

The cancer gene therapy market size has grown rapidly in recent years. It will grow from $4.21 billion in 2025 to $4.9 billion in 2026 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to advancements in molecular oncology research, expansion of clinical trials in gene therapy, increasing investment in biopharmaceutical R&D, regulatory approvals of early gene therapies, improved vector manufacturing capabilities.

The cancer gene therapy market size is expected to see rapid growth in the next few years. It will grow to $8.9 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to increasing demand for personalized cancer treatments, rising investment in cell and gene therapy manufacturing, expansion of next-generation viral vectors, growing focus on combination oncology therapies, increasing adoption of precision oncology approaches. Major trends in the forecast period include increasing development of targeted gene therapy platforms, rising adoption of CAR-T and TCR therapies, growing focus on viral vector optimization, expansion of personalized cancer gene treatments, enhanced integration of biomarker-guided therapy selection.

The rising incidence of cancer is expected to drive the growth of the cancer gene therapy market going forward. Cancer is a disease marked by the uncontrolled proliferation of abnormal cells that can invade other parts of the body, originating in various tissues and organs and classified according to the cell or tissue type from which it arises. The increase in cancer cases is fueled by longer life expectancy, as the likelihood of developing cancer grows with age. Cancer gene therapy addresses the disease by modifying or replacing defective genes to halt cancer cell growth or enhance the immune system’s capacity to eliminate them. For instance, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that over 3 million people in the UK are living with cancer, with projections reaching 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rising cancer incidence is propelling the growth of the cancer gene therapy market.

Major companies operating in the cancer gene therapy market are focusing on developing advanced treatments, such as CAR-T cell therapy, to improve treatment precision, enhance patient outcomes, and target cancer cells effectively while minimizing harm to healthy tissues. CAR-T therapy is a form of immunotherapy in which a patient’s immune cells are engineered with special receptors to better recognize and destroy cancer cells. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, launched NexCAR19 (actalycabtagene autoleucel), India’s first indigenously developed CAR-T cell therapy for cancer. Designed specifically for B-cell lymphomas and leukemias, NexCAR19 reprograms a patient’s T cells to identify and kill cancer cells. Based on advanced chimeric antigen receptor (CAR) technology, the therapy is locally manufactured, making it more affordable and accessible than imported alternatives. This launch represents a significant milestone for India in the global cancer gene therapy market, underscoring progress in domestic innovation and personalized cancer treatment.

In May 2025, AstraZeneca plc, a UK-based biopharmaceutical company, acquired EsoBiotec B.V. for an undisclosed amount. Through this acquisition, AstraZeneca aims to strengthen its cell therapy capabilities and accelerate the development of next-generation oncology and immune-mediated treatments. EsoBiotec B.V. is a Switzerland-based biotechnology company specializing in cancer gene therapies.

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.

North America was the largest region in the cancer gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cancer gene therapy market by increasing costs of imported viral vectors, cell processing equipment, bioreactors, reagents, and specialized manufacturing inputs. Biopharma companies and research institutions in North America and Europe are most affected due to reliance on cross-border supply chains, while Asia-Pacific faces cost pressure in scaling production facilities. These tariffs are increasing therapy development costs and extending commercialization timelines. However, they are also encouraging domestic biomanufacturing investments, regional supply chain development, and localized innovation in gene therapy platforms.

The cancer gene therapy market research report is one of a series of new reports that provides cancer gene therapy market statistics, including cancer gene therapy industry global market size, regional shares, competitors with a cancer gene therapy market share, detailed cancer gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cancer gene therapy industry. This cancer gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer gene therapy is a treatment approach that uses specific genes to target and fight cancer. It works by modifying or introducing genes into a patient’s cells to inhibit cancer growth and enhance the body’s ability to attack cancer cells. This strategy aims to provide more precise and less harmful treatment compared with traditional therapies.

The primary types of cancer gene therapies include gene-induced immunotherapy, oncolytic virotherapy, and gene transfer. Gene-induced immunotherapy involves using genes to strengthen the immune system, enabling it to better recognize and destroy cancer cells. These therapies are applied for various indications, including large B-cell lymphoma, multiple myeloma, acute lymphoblastic leukemia (ALL), melanoma, and others. They utilize different vector types, such as lentivirus, retrovirus and gamma retrovirus, adeno-associated virus (AAV), modified herpes simplex virus, adenovirus, and others. Key end users include hospitals, research institutes, biopharmaceutical companies, diagnostic centers, and other healthcare and research organizations.

The cancer gene therapy market consists of revenues earned by entities by providing services such as gene delivery services, clinical trial services, gene editing, and cell-based therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cancer gene therapy market also includes sales of gene therapy drugs, viral vectors, non-viral delivery systems, and plasmids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.